Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

In a report released yesterday, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with ...

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

The New York-based company said it had a loss of $1.54 per share. Losses, adjusted for non-recurring costs, were 96 cents per share. The results topped Wall Street expectations.

Operator Good morning, and welcome to the Axsome Therapeutics fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a ...

Highlights,Several major investment firms have adjusted their stakes in Axsome Therapeutics, reflecting evolving market ...